Authors found that higher FGF23 levels were associated with obesity, dyslipidemia (lower HDL cholesterol and apolipoprotein A1, higher triglyceride), and increased risk of presenting metabolic syndrome. This evidence concerns the gene APOA1 and metabolic syndrome.